Incorrect dosing requirements. The article “Treating Painful Diabetic Peripheral Neuropathy: An Update” (August 1, 2016, p. 227) incorrectly identified “no dosing adjustment requirement in patients with renal impairment” as a reason to prefer pregabalin to gaba-pentin as a first-line treatment option for painful diabetic peripheral neuropathy. However, according to the prescribing information for pregabalin, dosing changes are necessary relative to the creatinine clearance. The first full sentence of the right column on page 229 of the article should have read: “Pregabalin is preferred to gabapentin as a first-line medication because of the availability of higher-quality studies on its effects, more predictable pharmacokinetics, shorter titration periods, and the option for twice-daily dosing.” The online version of the article has been corrected.